Reply to: "Significant Hepatic Fat Loss after Metabolic Dysfunction-associated Steatotic Liver Disease: Beware of Misclassification as Absence of Disease" and "Risk stratification beyond fibrosis in SLD: The case for lifestyle-responsive prognostic tools" [0.03%]
对“代谢功能异常相关肝脂肪变性疾病后显著的肝脏脂肪减少：警惕错误分类为无病”的回应及“非酒精性脂肪性肝病风险分层超越纤维化：生活方式响应型预后工具的案例”
Terry Cheuk-Fung Yip,Vincent Wai-Sun Wong
Terry Cheuk-Fung Yip
Presence but low detection rate of rat Hepatitis E Virus in patients in Germany 2022-2024 [0.03%]
德国2022-2024年患者中存在但检测率低的实验鼠戊型肝炎病毒
Lisa Jasmin Mueller,Marie Luisa Schmidt,Sandra Ciesek et al.
Lisa Jasmin Mueller et al.
Dissecting metabolic dysfunction- and alcohol-associated liver disease (MetALD) using proteomic and metabolomic profiles [0.03%]
利用蛋白质组学和代谢组学谱型分析代谢功能紊乱和酒精相关性肝病(MetALD)
Jun Liu,Sihao Xiao,Sile Hu et al.
Jun Liu et al.
Background: & Aim, Metabolic dysfunction associated and alcohol associated liver disease (MetALD) is a poorly understood condition that bridges cardiometabolic and alcohol-related pathological characteristics. We aim to d...
Prior Hepatitis E virus (HEV) genotype 1 infection is not protective against rat HEV infection in Mongolian gerbils [0.03%]
蒙古旱獭感染人戊型肝炎病毒第一个基因型不能防止再次感染鼠戊型肝炎病毒感染
Tianxu Liu,Xinyue Yang,He Zhang et al.
Tianxu Liu et al.
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer [0.03%]
候选替代终点与晚期胆道癌总生存期的相关性分析
Florian Castet,Carles Fabregat-Franco,John Bridgewater et al.
Florian Castet et al.
Background & aims: The use of surrogate endpoints in trials including biliary tract cancers (BTC) is growing. While this may expedite drug approval and decrease costs, it may not always correlate with an overall survival ...
Bringing genetic testing into the clinical management of people with MASLD: are we there yet? [0.03%]
遗传检测在MASLD临床管理中的应用：我们准备好了吗？
Luca Valenti,Hannes Hagström
Luca Valenti
Re: Differential HBV RNA and HBcrAg patterns in untreated patients with chronic hepatitis delta [0.03%]
未经治疗的慢性δ肝炎患者的差异性HBV RNA和HBcrAg模式
James Lok,Zillah Cargill,Mark Anderson et al.
James Lok et al.
Personalized survival benefit estimation from living donor liver transplantation with a novel machine learning method for confounding adjustment [0.03%]
利用新型机器学习法修正混杂因素后估计肝移植生存受益的个性化评估方法
Anirudh Gangadhar,Bima J Hasjim,Xun Zhao et al.
Anirudh Gangadhar et al.
Background & aims: Many clinical questions, such as estimating survival differences between living donor (LDLT) and deceased donor liver transplantation (DDLT), are limited to observational studies and cannot be answered ...